Longevity Biotech receives award to evaluate novel drug candidate for MS in preclinical models
News medical life Sciences | October 30, 2017
Longevity Biotech, Inc. (LBT) has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society's commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent.